Correction: Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-05-01
|
| Series: | The Journal of Headache and Pain |
| Online Access: | https://doi.org/10.1186/s10194-022-01423-x |
| _version_ | 1818549697515618304 |
|---|---|
| author | Stephanie J. Nahas Steffen Naegel Joshua M. Cohen Xiaoping Ning Lindsay Janka Verena Ramirez Campos Lynda J. Krasenbaum Dagny Holle-Lee David Kudrow Christian Lampl |
| author_facet | Stephanie J. Nahas Steffen Naegel Joshua M. Cohen Xiaoping Ning Lindsay Janka Verena Ramirez Campos Lynda J. Krasenbaum Dagny Holle-Lee David Kudrow Christian Lampl |
| author_sort | Stephanie J. Nahas |
| collection | DOAJ |
| first_indexed | 2024-12-12T08:36:44Z |
| format | Article |
| id | doaj.art-2cfef4f751454da4afcac2578f838a35 |
| institution | Directory Open Access Journal |
| issn | 1129-2369 1129-2377 |
| language | English |
| last_indexed | 2024-12-12T08:36:44Z |
| publishDate | 2022-05-01 |
| publisher | BMC |
| record_format | Article |
| series | The Journal of Headache and Pain |
| spelling | doaj.art-2cfef4f751454da4afcac2578f838a352022-12-22T00:30:54ZengBMCThe Journal of Headache and Pain1129-23691129-23772022-05-012311410.1186/s10194-022-01423-xCorrection: Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studiesStephanie J. Nahas0Steffen Naegel1Joshua M. Cohen2Xiaoping Ning3Lindsay Janka4Verena Ramirez Campos5Lynda J. Krasenbaum6Dagny Holle-Lee7David Kudrow8Christian Lampl9Department of Neurology, Thomas Jefferson UniversityDepartment of Neurology, University Hospital Halle (Saale) and University Halle-WittenbergTeva Pharmaceutical IndustriesTeva Pharmaceutical IndustriesTeva Pharmaceutical IndustriesTeva Pharmaceutical IndustriesTeva Pharmaceutical IndustriesDepartment of Neurology and Westgerman Headache Center Essen, University HospitalCalifornia Medical Clinic for HeadacheHeadache Medical Centrehttps://doi.org/10.1186/s10194-022-01423-x |
| spellingShingle | Stephanie J. Nahas Steffen Naegel Joshua M. Cohen Xiaoping Ning Lindsay Janka Verena Ramirez Campos Lynda J. Krasenbaum Dagny Holle-Lee David Kudrow Christian Lampl Correction: Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies The Journal of Headache and Pain |
| title | Correction: Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies |
| title_full | Correction: Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies |
| title_fullStr | Correction: Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies |
| title_full_unstemmed | Correction: Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies |
| title_short | Correction: Efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies |
| title_sort | correction efficacy and safety of fremanezumab in clinical trial participants aged ≥60 years with episodic or chronic migraine pooled results from 3 randomized double blind placebo controlled phase 3 studies |
| url | https://doi.org/10.1186/s10194-022-01423-x |
| work_keys_str_mv | AT stephaniejnahas correctionefficacyandsafetyoffremanezumabinclinicaltrialparticipantsaged60yearswithepisodicorchronicmigrainepooledresultsfrom3randomizeddoubleblindplacebocontrolledphase3studies AT steffennaegel correctionefficacyandsafetyoffremanezumabinclinicaltrialparticipantsaged60yearswithepisodicorchronicmigrainepooledresultsfrom3randomizeddoubleblindplacebocontrolledphase3studies AT joshuamcohen correctionefficacyandsafetyoffremanezumabinclinicaltrialparticipantsaged60yearswithepisodicorchronicmigrainepooledresultsfrom3randomizeddoubleblindplacebocontrolledphase3studies AT xiaopingning correctionefficacyandsafetyoffremanezumabinclinicaltrialparticipantsaged60yearswithepisodicorchronicmigrainepooledresultsfrom3randomizeddoubleblindplacebocontrolledphase3studies AT lindsayjanka correctionefficacyandsafetyoffremanezumabinclinicaltrialparticipantsaged60yearswithepisodicorchronicmigrainepooledresultsfrom3randomizeddoubleblindplacebocontrolledphase3studies AT verenaramirezcampos correctionefficacyandsafetyoffremanezumabinclinicaltrialparticipantsaged60yearswithepisodicorchronicmigrainepooledresultsfrom3randomizeddoubleblindplacebocontrolledphase3studies AT lyndajkrasenbaum correctionefficacyandsafetyoffremanezumabinclinicaltrialparticipantsaged60yearswithepisodicorchronicmigrainepooledresultsfrom3randomizeddoubleblindplacebocontrolledphase3studies AT dagnyhollelee correctionefficacyandsafetyoffremanezumabinclinicaltrialparticipantsaged60yearswithepisodicorchronicmigrainepooledresultsfrom3randomizeddoubleblindplacebocontrolledphase3studies AT davidkudrow correctionefficacyandsafetyoffremanezumabinclinicaltrialparticipantsaged60yearswithepisodicorchronicmigrainepooledresultsfrom3randomizeddoubleblindplacebocontrolledphase3studies AT christianlampl correctionefficacyandsafetyoffremanezumabinclinicaltrialparticipantsaged60yearswithepisodicorchronicmigrainepooledresultsfrom3randomizeddoubleblindplacebocontrolledphase3studies |